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Abstract
Background:  Resveratrol is a polyphenol with important antiinflammatory and antioxidant
properties. We investigated the effect of resveratrol on alcohol-induced mortality and liver lesions
in mice.
Methods: Mice were randomly distributed into four groups (control, resveratrol-treated control,
alcohol and resveratrol-treated alcohol). Chronic alcohol intoxication was induced by
progressively administering alcohol in drinking water up to 40% v/v. The mice administered
resveratrol received 10 mg/ml in drinking water. The animals had free access to standard diet.
Blood levels were determined for transaminases, IL-1 and TNF-α. A histological evaluation was
made of liver damage, and survival among the animals was recorded.
Results: Transaminase concentration was significantly higher in the alcohol group than in the rest
of the groups (p < 0.05). IL-1 levels were significantly reduced in the alcohol plus resveratrol group
compared with the alcohol group (p < 0.05). TNF-α was not detected in any group. Histologically,
the liver lesions were more severe in the alcohol group, though no significant differences between
groups were observed. Mortality in the alcohol group was 78% in the seventh week, versus 22% in
the alcohol plus resveratrol group (p < 0.001). All mice in the alcohol group died before the ninth
week.
Conclusion: The results obtained suggest that resveratrol reduces mortality and liver damage in
mice.
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Background
Alcohol abuse is a major cause of liver disease in Western
countries. In the United States it has been estimated that
there are some 25,000 deaths from cirrhosis yearly, about
half of which are related with alcohol [1]. The cirrhosis
death rate (irrespective of cause) in the United States is
about 12 per 100,000 population, while the 5 and 10-year
survival rates for alcoholic cirrhosis are reported at 23%
and 7%, respectively, much worse than other types of cir-
rhosis [1].
Alcohol can cause liver damage in the form of steatosis or
fatty liver, hepatitis, fibrosis and liver cirrhosis. In general,
the amount and duration of alcohol abuse correlate with
the presence and severity of liver damage, at least as
regards the initial stage of fatty liver [2]. It is still uncer-
tain, however, why only 20–30% of long-term alcohol
abusers develop severe liver disease. For instance, one
study estimated that cirrhosis develops in only 14% of
alcoholics consuming 160 g of alcohol (12 drinks) per
day for 8 years [1]. The relatively low incidence of severe
liver damage in alcoholics and the poor correlation
between the amount of alcohol and the severity of the dis-
ease suggest that in addition to genetic influences, the
pathogenesis of alcoholic liver disease involves other
important environmental factors [3-5].
One hypothesis is that substances such as polyphenols
may be present in the diet, or even in alcoholic beverages,
thereby contributing to inhibit alcohol induced damage.
Polyphenols possess a variety of biological functions,
including antioxidant, anti-inflammatory, and anticancer
effects. Resveratrol is a phytoalexin polyphenolic com-
pound found in various plants, including grapes, berries,
and peanuts. Multiple lines of compelling evidence indi-
cate its beneficial effects on neurological, hepatic, and car-
diovascular systems. Resveratrol has also been reported to
have anti-cancer, anti-mycotic, and anti-bacterial proper-
ties [6-9].
Among the possible mechanisms responsible for its bio-
logical activities are downregulation of the inflammatory
response through inhibition of synthesis and release of
pro-inflammatory mediators, modification of eicosanoid
synthesis, inhibition of Kupffer cells and adhesion mole-
cules, inhibition of activated immune cells, or inhibition
of inducible nitric oxide synthase (iNOS) and cyclooxyge-
nase-2 (COX-2) via its inhibitory effects on nuclear factor
(kappa)B (NF-(kappa)B) or the activator protein-1 (AP-1)
[5,10-12]. Pharmacokinetic studies revealed that the tar-
get organs of resveratrol are liver and kidney, where it is
concentrated after absorption and is mainly converted to
a sulfated form and a glucuronide conjugate [13].
The present study investigates whether resveratrol is able
to reduce alcohol-induced mortality and liver damage in
mice.
Methods
Animals and diets
Male Balb/c mice (CRIFFA, Barcelona, Spain) weighing
about 26 g were used. All experiments were conducted in
accordance with the Guide for the Care and Use of Labo-
ratory Animals published by the US Public Health Service.
Animals were maintained on a regular 12-hour light
period at a controlled temperature (25 ± 2°C), with free
access to food and water. The mice were adapted for 2 to
5 days prior to initiation of the experimental protocol.
The diet consisted of 58.5% carbohydrates, 15.5% pro-
teins, 2.7% fat, 5.5% minerals, 3.7% fiber and 12%
humidity (PANLAB, Barcelona, Spain). The caloric con-
tents were 3000 kcal/kg.
Experimental procedures
Mice were distributed into four groups: control, resvera-
trol-treated control, alcohol and resveratrol-treated alco-
hol. Resveratrol was obtained from SIGMA Chemical,
(Pool, Dorset) and alcohol from PRS.PANREAC. In order
to induce alcoholic intoxication, pure alcohol was pro-
gressively diluted in the drinking water: 10% (v/v) alcohol
in the first week, 20% in the second, 30% in the third, and
40% in the fourth and subsequent weeks until the end of
the study. Resveratrol (10 mg/ml) was also added to the
water. Liquids and food were changed twice a week and
the animals were monitored daily for general health.
The timing of sacrifice for the study of liver damage was
determined from previous trials in which mortality was
seen to be very high after the sixth week. The animals were
killed at 6 weeks using intraperitoneal pentobarbital
(Nembutol). The animals destined for the evaluation of
mortality were followed until death.
The mortality and liver-damage studies were each
repeated on three occasions to confirm the histological
and laboratory alterations (6 mice per group, for a total of
18 animals per group) and again on three occasions to
confirm the mortality curves (6 mice per group, for a total
of 18 animals per group).
Laboratory tests
At the time of sacrifice alcohol in blood was determined
by the AxSYM REA assay, a quantitative reagent system for
the measurement of ethanol in murine whole blood
(Abbott Axsym System). Laboratory parameters such as
AST, ALT, creatinine, urea, total cholesterol, triglycerides,
GGT, amylases, total bilirubin and hematocrit were deter-
mined on a computer-controlled biochemical analyzer.BMC Gastroenterology 2006, 6:35 http://www.biomedcentral.com/1471-230X/6/35
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Determination of IL-1 and TNF-α
Serum TNF-α and IL-1β concentrations were measured
using ELISA kits based on anti-mouse TNF-α and IL-1β
monoclonal antibodies (R&D Systems, Boston, MA).
Liver histology
The histological study was conducted following a midline
laparotomy to remove the liver. Samples of liver tissue
removed at the time the mouse was killed were placed
immediately in 10% buffered formalin and subsequently
embedded in paraffin. Sections were stained with hema-
toxylin and eosin using standard techniques. Sections
were viewed without knowledge of the treatment group to
which each animal had belonged.
Statistical analysis
Quantitative data were expressed as an average ± SD for
the different animals in each group, and comparisons
were made using the 2-tailed Student's t test. P values of <
0.05 were considered statistically significant.
Results
Mortality
The mortality curves were similar in all three test series.
The mice in the alcohol group began to die after the sec-
ond week of alcohol intoxication, with a survival of 22%
(4/18) in the seventh week. None of the mice survived
beyond eight weeks. The animals belonging to the alcohol
plus resveratrol group began to die later (after the fourth
week, involving a single mouse), with a survival of 78%
(14/18) in the seventh week. The control and resveratrol
groups in turn presented survivals of 100% and 89% (16/
18), respectively, in the seventh week (Figure 1). Survival
was significantly lower in the alcohol group than in the
other three groups (p < 0.001).
The mice subjected to alcohol intoxication showed a
poorer general condition after the second week, as
reflected by decreased activity, immobility, grouping and
coarse hair. No such differences were observed in the
other three groups (control, resveratrol and alcohol plus
resveratrol).
Food and water intake
The average food intake among the control rats was 4.27
± 0.86 g/day, which was similar to the consumption in the
resveratrol group (4.47 ± 0.63 g/day). The alcohol group
and the alcohol plus resveratrol group showed an impor-
tant reduction in food intake, with 3.28 ± 0.86 and 3.11 ±
0.51 g/day, respectively. These differences between the
Survival of the different groups of mice over time (weeks) Figure 1
Survival of the different groups of mice over time (weeks). Mortality was of 100% at 8 weeks in the alcohol (OH) group and 
only 50% in the (OH-Resveratrol) group. (OH; alcohol group).BMC Gastroenterology 2006, 6:35 http://www.biomedcentral.com/1471-230X/6/35
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group with alcohol and the groups without alcohol were
statistically significant (p < 0.05).
Similar observations applied to liquid consumption,
which on average was similar in the control group and in
the resveratrol group (5.98 ± 2.07 ml/day and 5.50 ± 0.10
ml/day, respectively), while the liquid consumed in the
alcohol groups was comparatively less (3.14 ± 1.46 ml/
day in the alcohol group and 2.97 ± 0.97 ml/day in the
alcohol plus resveratrol group)(p < 0.05). Each mouse on
the alcohol and alcohol plus resveratrol groups did
ingested approximately 3 ml, that is, around 30 mg of res-
veratrol and 0.24 g of alcohol per day.
Body weight in the control and resveratrol group was
maintained during the study, while the corresponding val-
ues in the alcohol groups were seen to decrease (p <
0.05)(Figure 2). The drop in body weight was more pro-
nounced in the group administered alcohol only,
although there were no significant differences compared
with the alcohol plus resveratrol group.
Laboratory findings
ALT concentration in the alcohol group was significantly
higher than in the rest of the groups (p < 0.001). AST con-
centration in the alcohol group was significantly higher
than in the alcohol plus resveratrol group (p < 0.05). Stas-
tiscally significant differences in AST levels were also
observed between the two groups with alcohol and the
two groups without alcohol (p < 0.05) (Fig. 3).
The AST/ALT ratio in the control series and resveratrol
group was 3.4 and 3.5, respectively. In contrast, the ratio
in the alcohol group and alcohol plus resveratrol group
was 1.87 and 4.16, respectively.
The values for alkaline phosphatase (AP) were 208.5 ±
16.5 U/l in the control group and 209 ± 14 U/l in the res-
veratrol group. AP in the alcohol plus resveratrol group
was higher (262 ± 17 U/l) than in the alcohol group
(237.5 ± 15 U/l)(p = 0,5).
There were no differences in terms of the other laboratory
parameters such as creatinine, urea, total cholesterol, trig-
lycerides, GGT, amylases, total bilirubin and hematocrit.
Body weights of the mice at the start, half-way and at the end of the study Figure 2
Body weights of the mice at the start, half-way and at the end of the study. Weight increase was observed in the control and 
resveratrol groups while a decrease existed in the alcohol group. Weight decrease was less evident in the OH-Resveratrol 
group. P < 0.05 vs. control group and resveratrol group. (OH; alcohol group).
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Arterial blood alcohol determinations revealed a mean
value of 34.73 mg/dl (range 15.52 – 55.45 mg/dl) among
the mice administered alcohol in water solution, while no
alcohol was detected in the blood in any of the control or
resveratrol groups.
Interleukins
Figure 4 shows that the IL-1 levels were increased in the
alcohol group versus the rest of the groups (p < 0.05). The
blood levels of IL-1 in the alcohol plus resveratrol mice
were even lower than in the control group and resveratrol-
treated control group. The blood levels of IL-1 in the alco-
hol plus resveratrol mice were lower than in the alcohol
group (p < 0,001). TNF-α was not detected in any group.
Histological evaluation
The histological liver lesions were mild in the alcohol and
alcohol plus resveratrol groups compared with the labora-
tory alterations and critical condition of the mice. The
observed lesions consisted of moderate mixed lympho-
monocytic infiltrations with steatosis ranging from 10–
15% (Figure 5). No fibrosis or liver cirrhosis was
observed.
Discussion
Alcohol is toxic for both humans and animals, and exerts
important negative effects upon the liver, brain, heart,
skeletal muscle, pancreas, hematological and immune
systems, gastrointestinal apparatus and endocrine system
[14,15]. Chronic alcohol abuse induces multiorgan dete-
rioration with an increase in mortality. In humans, for
example, alcoholics with severe denutrition suffer a 54%
mortality rate after 12 months versus 9% among patients
with mild denutrition [16]. The present experimental
study found chronic (6 weeks in mice with an average
lifespan of two years) and severe alcohol intoxication
(40% of all fluid intake in the form of alcohol) to cause
increased mortality after the second week. Food and alco-
hol intake was similar in the alcohol and alcohol plus res-
veratrol mice groups but a strong difference in mortality
was observed between them. The cause of death was not
known, though the most likely explanation is multiorgan
failure secondary to denutrition, coagulation disorders
(hypercoagulability was seen in the alcohol group, thus
complicating blood extraction), liver alterations,
increased infections and endotoxemia. Oxidative stress
and endotoxin (lipopolysaccharide (LPS)) are commonly
AST and ALT plasma levels in each group are shown Figure 3
AST and ALT plasma levels in each group are shown. * P < 0.05 vs. other groups.
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elevated in the blood of alcoholics and in certain animal
models of alcoholic liver disease [17]. It causes the release
of a battery of cytokines from macrophages and other
cells. Reactive oxygen species are capable of damaging the
cell in many ways. They have been shown to react with all
major classes of cellular constituents: lipids, proteins and
nucleic acids. It is well established that chronic ethanol
administration leads to oxidative stress in the liver and
other organs [18]. Thus, a high amount of alcohol intake,
as observed in this model, has deleterious effects on circu-
latory, immune and neural systems as well as on blood
elements, endocrine glands, pancreas, liver and muscles
and bone leading to increased in mortality [19].
Alcoholic patients have a high prevalence of protein-calo-
rie malnutrition and vitamin deficiencies [20,21]. In our
study a significant decrease was observed in food inges-
tion and body weight among the alcohol-consuming
mice. There are many reasons for malnutrition, perhaps
the most important of which is decreased intake of nutri-
ents. Calories derived from alcohol, are called "empty cal-
ories"., in reference to the fact that alcohol, which has 7.1
kcal/g, is not utilized properly by the body as a nutrient
[22]. Thus, its intake is not associated with normal
(expected) weight gain. The reasons for decreased intake
of foods are many and include alcohol per se, presence of
liver disease, impairment of the taste and smell acuity,
maldigestion (decrease in bile salts or lipase), malabsorp-
tion (changes in gut mucosa and its enzymes, altered per-
meability, changes in motility and possibly gut edema)
[23].
The alcohol plus resveratrol group showed an important
decrease in mortality. The mechanisms by which resvera-
trol reduces alcohol-induced mortality are not clear,
though its antioxidant, antiinflammatory and antiinfec-
tious properties may play a role [5-7,10,23]. Resveratrol
also suppresses the expression of inducible nitric oxide
Serum concentrations of interleukin-1 (IL-1) in the different groups Figure 4
Serum concentrations of interleukin-1 (IL-1) in the different groups. The control group and resveratrol group showed higher 
plasma levels than those observed in the alcohol plus resveratrol group. * P < 0.05 vs. control group, Δ P < 0,001 vs alcohol 
group.
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synthase and cyclooxygenase-2, is a potent inhibitor of
nuclear factor kB (NF-kB) nuclear translocation by block-
ing kB kinase activity, and decreases platelet aggregation
[24-28]. In our study, one mouse died in the resveratrol
group. This death may have been due to aggression
between individuals, as this mouse had paw lesions. In
another published study involving resveratrol adminis-
tered orally to mice at doses similar to our own, no
increased mortality in the resveratrol group versus the
controls was likewise observed [29].
The chronic consumption of high doses of alcohol can
cause liver damage and cirrhosis in humans. However, in
animals it is very difficult to establish an experimental
model of alcoholic liver disease. Very few such models
have been developed, and most do not involve only alco-
hol, i.e., they also include additional elements such as
hypercaloric diets, iron, endotoxins or other toxins. The
model closest to reality (animals with free access to food
and drink) is that described by Tsukamoto et al. [30],
though it induces alcoholic liver disease by administering
a diet rich in polyunsaturated fats and alcohol through a
nasogastric tube. Our own model attempts to reproduce
situations as close as possibly to reality, i.e., the mice are
able to spontaneously eat (standard diet) and drink as
much as they want, without the influence of factors that
enhance the liver damaging capacity of alcohol. The alco-
hol concentration in mouse arterial blood was modest,
since alcohol consumption was irregular (i.e., free access).
This may possibly be the reason why the blood alcohol
concentrations and liver lesions in the mice were modest.
The alcoholic intoxication model employed, and proba-
bly also the action of genetic factors, yields moderate liver
damage without either liver fibrosis or cirrhosis – despite
the high alcohol concentrations involved. In unpublished
studies we found that liver cirrhosis could not be achieved
in mice given lower doses of alcohol for longer periods of
time (20% of drinking volume for 6 months).
Although cirrhosis could not be induced, the alcohol
group showed a moderate increase in transaminase levels,
with a greater rise in ALT, as occurs in alcoholic liver dis-
ease [31]. These increased laboratory values are not
directly correlated to the histological severity of the dis-
Liver sections from mice in control group (A) and resveratrol group (B) showed normal liver histology Figure 5
Liver sections from mice in control group (A) and resveratrol group (B) showed normal liver histology. Liver sections from a 
mouse in alcohol group showed mixed lympho-monocytic infiltrations around the portal vein (C). Mild steatosis with small fat 
droplets in the liver obtained from a mouse in alcohol group (D).
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ease as in humans [32]. The generation of free radicals as
a result of alcohol did not correlate with elevated pathol-
ogy scores in the liver or high ALT levels and acts as redox
signals for cytokine production but does not directly dam-
age the liver [33]. Resveratrol decreased the liver labora-
tory values and the corresponding liver damage –
probably as a result of the diminished release of proin-
flammatory cytokines such as IL-1 as a result of Kupffer
cell activation. In this context, over 75% of all individuals
with alcoholic hepatitis have increased plasma IL-1 levels
[34,35]. TNF-alfa serum levels have been related to mor-
tality and the severity of the hepatic lesions observed in
humans and produced by alcohol intake [35,36]. How-
ever TNF-alfa levels are poor diagnostic markers for the
severity of TNF-dependent liver inflammation [37]. Other
studies dealing with plasma levels of TNF-alfa and IL-1 in
response (LPS), indicate that the TNF-alfa plasma level
rises soon after the injection of LPS and that is the reason
why it cannot be observed in our study. Otherwise IL-1
remains elevated for a longer period of time. This can be
explained by augmented clearance of TNF-alfa not affect-
ing IL-1, a smaller systemic inflammatory response or to
neutralization of TNF-alfa by a soluble receptor resulting
in a marked attenuation of the late phase of the alcohol
action [38].
Both IL-1 and TNF-alfa are produced after macrophage
activation and produce an endothelial activation process
leading to an increase of adhesion molecules expression,
secretion of other cytokines, growth factors, ecosanoid
production, nitric oxide and increased endothelial throm-
bogenicity. Both cytokines produce fibroblast activation
leading to proliferation and augmented extracellular
matrix synthesis. IL-1 and TNF-alfa produce stimulation
of the acute phase systemic manifestation including som-
nolence, fever, changes in liver protein synthesis, changes
in metabolism (caquexia), PMN migration, ACTH libera-
tion and augmented steroid liberation [39].
Other effects of resveratrol upon on the liver can be the
inhibition of nitric oxide production by the Kupffer cells
[5] and antioxidant action similar to that of other sub-
stances such as S-adenosylmethionine [40].
Conclusion
Resveratrol reduces mortality and liver damage produced
by alcohol in mice. If our findings are confirmed by fur-
ther research, resveratrol could be administered to
patients with chronic alcoholism to reduce the mortality
and liver damage associated with alcohol abuse. It could
even be prophylactically added to alcoholic beverages, in
a way similar (10 mg/L of any alcoholic beverage), similar
to how chlorine is added to water to prevent infections.
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